Rheumatology

Article	Citations
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?	127
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	93
Boxer’s shape, an unusual finding in nailfold capillaroscopy	85
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	66
Editor’s Acknowledgement	63
Clinical and serological resolution of pembrolizumab associated Sjögren’s syndrome: long-term follow-up	63
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	61
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	56
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	55
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	54
Comment on: Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease	50
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	49
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	48
Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study	48
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	47
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	47
Haematologic malignancy-associated mucocutaneous paraneoplastic syndrome	47
The role of IL-23 in joint disease	45
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	45
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	43
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	43
Annular erythematous plaques as manifestation of vasculitis in pediatric Sjögren’s syndrome	43
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	43
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	43
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort	41

Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	41
Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	41
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	40
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study	39
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment	39
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	39
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review	39
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis	38
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	38
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE	37
Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis	37
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	36
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	36
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients	36
Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis	35
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?	35
Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study	35
Type I interferon dysregulation drives distinct pathogenic pathways in early- and late-onset lupus nephritis	34
Comment on: Predictors of lack of response to methotrexate in juvenile idiopathic arthritis–associated uveitis	34
Bezoar secondary to NSAID use in a patient with inflammatory arthritis	34
P041 Successful reversal of microvascular damage with standard therapy in a case of dermatomyositis overlap syndrome	34
Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic and imaging associations	34
Examination of nailfold videocapillaroscopy findings in ANCA-associated vasculitis	34
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals	34
E051 Audit of the management of patients over 75 with osteoporotic fragility fractures in primary care	34
Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis	33
P004 Empowering the reproductive choices of patients with rheumatic disease: using the BSR 2022 pregnancy guidelines audit tool to evaluate pre-conception medication advice	33
P114 Medication adherence to b/tsDMARDS remains sub-optimal in refractory rheumatoid arthritis	32
The state of data sharing in rheumatology: a systematic review of top journal practices	32
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	32
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	32
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	32
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	31
Lupus serology: off target but still relevant to the treat-to-target strategy in systemic lupus erythematosus	31
54 Kawasaki disease: experience in a general paediatric department of the CHU de Annaba Algeria	30
P174 Identifying patterns of fatigue across flares in patients with axial spondyloarthritis	30
P083 Undergraduate rheumatology teaching in the UK: a survey of teachers	30
P143 Frailty is associated with inflammation, impaired glucose metabolism and reduced bone mineral density after adjustment for fat mass index: a UK biobank study	30
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	29
P185 Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index	29
P004 Temporal and regional variation in the initiation of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study	29
P077 Developing a better explanation of osteoarthritis: results from a conjoint analysis of patient preferences	29
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years	29
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	29
P179 A feasibility randomised controlled trial of a fibromyalgia self-management programme in a community setting with a nested qualitative study	29
Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis	29
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	28
P031 Adherence with Methotrexate in Tunisian Juvenile Idiopathic Arthritis Patients	28
Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy	28
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	28

P011 Rituximab and COVID-19 vaccines; are they fit for purpose?	28
P133 Experiences of people with digital ulcers through filmed interviews	28
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	27
26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	27
E046 Lytic lesions; metastatic disease or gout?	27
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	27
OA22 Methotrexate drug monitoring and referral patterns to Hepatology - can we improve detection and monitoring of hepatoxicity with methotrexate use?	27
P131 Adult coeliac disease and bone mineral density at the femoral neck, total hip and lumbar spine: an age- and sex-matched case-control study	27
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	27
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	27
P033 The intriguing association between fibromyalgia, hypermobility and neurodivergence: a pilot study	27
OA04 COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a national cohort	26
P032 Methotrexate and hepatic tolerance in Juvenile Idiopathic Arthritis	26
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	26
Enhancing Gout Diagnosis with Deep Learning in Dual-energy Computed Tomography: A Retrospective Analysis of Crystal and Artifact Differentiation	25
P047 Musculoskeletal symptoms as first clinical presentation of juvenile-onset systemic lupus erythematosus: Experience from a military internal medicine department	25
P073 Functional investigation of Osteoarthritis-associated non-coding variants using CRISPR/Cas9-mediated perturbation of active enhancer regions	25
The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial	25
P025 Risk assessment of covid 19 in patients with Juvenile Idiopathic Arthritis	25
P261 Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom	25
OA44 Increasing access to rehabilitation for knee and hip osteoarthritis - ESCAPE-pain in leisure/community centres	25
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus	25
P038 Let’s look at coxitis features in enthesitis-related arthritis population	25
Avacopan may not independently reduce ANCA titres in ANCA-associated vasculitis: a retrospective analysis of 57 patients	25
The usefulness of ultrasound in predicting outcomes in patients with shoulder pain: a prospective observational study	25
IGFBP5 regulates fibrocartilage differentiation and cartilage injury induced by T-2 toxin via blocking IGF-1/IGF-1R signalling	24
The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus	24
Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests	24
Negative back beliefs are associated with increased odds of low back pain and disability: a 10-year cohort study in men	24
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort	24
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis	24
Corrigendum to: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from EUROAPS registry	24
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity	24
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease	24
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE	24
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study	24
VEXAS syndrome mimicking lupus-like disease	23
High levels of EPSTI1 enhance IFN-β-mediated HLA-A expression and chemokine secretion in myoblasts in dermatomyositis	23
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis	23
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet’s disease versus the general population	23
Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers—an observational study	23
Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study	23
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis	23
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis	23
Esophageal dysmotility patterns are associated with distinct clinical phenotypes and prognosis in patients with systemic sclerosis	23
Impaired humoral and T helper cell responses to toxic shock syndrome toxin-1 (TSST-1) in granulomatosis with polyangiitis	23
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	23
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib	23
Giant cell arteritis of the prostate	22
Correction to: Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region	22
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles	22
Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3	22
Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status	22
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate	22
COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis	22
The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership	22
Correction to: TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis	22
History of tonsillectomy is associated with glandular inflammation in Sjögren’s disease	22
Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study	21
Tofacitinib as a possible treatment for arthritis in an APDS2 patient	21
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis	21
Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy	21
Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus–associated refractory cerebral vasculitis induces immune tolerance	21
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry	21
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study	21
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation	21
Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases	21
Is the relationship between deprivation and outcomes in rheumatoid arthritis mediated by body mass index? A longitudinal cohort study	21
Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome	21
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis	21
Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients	21
Comment on: Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk: reply	20
Giant thymic cyst overclouding the diagnosis of fibrodysplasia ossificans progressiva: an inconvenient coincidence	20
HLA-C*06–defined endotype in psoriatic disease: an ever-widening landscape	20
When should we start screening for hydroxychloroquine retinopathy?	20
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease	20
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders	20
It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis	20
Sarcoid myopathy: an insidious diagnosis that can mimic inclusion body myositis	20
Assessing the role of climate and the environment as co-factors for vasculitis diseases	20

Emerging targeted therapies in ANCA-associated vasculitis	20
Increased risk of myocarditis and arrythmias in anti-Ku-positive scleroderma–myositis overlap patients: a case series	20
Predicting treatment response to methotrexate: are we closer to solving the enigma?	20
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care	20
Registry based studies on pregnancy and rheumatic diseases: generating actionable evidence	20
Discordance in patient and physician global assessment in relapsing polychondritis	20
Osteophytes’ position in subjects with DISH and right-sided aorta: verification of the ‘aortic pulsation protective effect’ theory	20
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis	20
Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis	20
Corrigendum to: Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden	20
Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down	20
Risk of venous thromboembolism in people with RA: a population-based study in the UK	20
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study	20
Teledidactic peer-tutored musculoskeletal ultrasound training for medical students—the TELMUS study	20
Correction to: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis	19
Comment on: Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports	19
Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis	19
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis	19
Quantitative chest imaging and prediction of mortality in rheumatoid arthritis–associated interstitial lung disease	19
Interplay between genetics and lifestyle on pain susceptibility in women with fibromyalgia: the al-Ándalus project	19
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances	19
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry)	19
Use of primary health care and radiological imaging preceding a diagnosis of rheumatoid arthritis: a nationwide cohort study in Denmark	19
Ultrasound subclinical synovitis in anti-CCP-positive at-risk individuals with musculoskeletal symptoms: an important and predictable stage in the rheumatoid arthritis continuum	19
Raynaud’s phenomenon and digital ischaemia induced by ixekizumab	19
Comment on: The clinical and cost effectiveness of splints for thumb base osteoarthritis: a randomized controlled clinical trial	19
Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort	19
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews	19
Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study	19
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	19
Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study	19
Avacopan in an ocular complication of ANCA-PR3 vasculitis without kidney involvement	19
Erratum to: Parvovirus B19 induces cellular senescence in human dermal fibroblasts: putative role in systemic sclerosis-associated fibrosis	19
Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthri	18
P208 PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population	18
P027 Infliximab in the treatment of cerebral tuberculosis paradoxical reactions with vasculitis	18
P046 The influence of deprivation in the outcomes of Psoriatic Arthritis within the UK - utilising Outcomes of Treatment in Psoriatic Arthritis Study Syndicate data	18
P284 Evaluation of a self-management smartphone app for those living with Sjögren’s syndrome: a fully remote randomised pilot and feasibility trial	18
P212 Understandings and responses to joint pain: preliminary findings from a rapid ethnographic assessment in Northern Tanzania	18
Experience with upadacitinib in refractory polyarticular juvenile idiopathic arthritis	18
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study	18
E68 Kawasaki Disease before and during COVID-19	18
P110 Characteristics of Difficult to treat Rheumatoid Arthritis patients in a large District Hospital in the UK	18
OA06 Single-centre experience of the use of Rituximab for inflammatory arthritis during the COVID-19 pandemic	18
20 Does hip involvement affect foot and ankle in juvenile idiopathic arthritis?	18
P083 Primary Goujerot- Sjögren Syndrome: a pediatric case report	18
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment	18
P133 Attitudes to Technology supported Rheumatoid Arthritis care: Opportunities & Barriers for technology in RA - Key themes from Qualitative arm of Mixed-Methods Study	18
E71 Distribution of cells and extracellular matrix in the normal marginal synovium of the hip joint capsule during the postnatal period	18
OA01 Cluster medicine: the role of genetics for identifying shared biological pathways between rheumatoid arthritis and common comorbidities for targeting treatments	18
OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study	18
E005 Investigation into the post-diagnostic care and follow-up of patients with giant cell arteritis post-initiation of long-term glucocorticoids at University Hospitals Leicester NHS Foundation Trust	18
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study	17
P094 Experts in lived experience: CLUSTER Champions and their successful collaboration in JIA research	17
E005 An audit of demographics, symptoms & investigations: Part of the survey of GCA in the SEHSCT during the COVID-19 pandemic	17
P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome	17
Nailfold videocapillaroscopy findings correlate with lung outcomes in idiopathic inflammatory myopathies–related interstitial lung disease	17
P163 The cytokine horror: Kawasaki disease shock syndrome complicated with macrophage activation syndrome	17
E001 Pre-screen chest X-ray before starting methotrexate in autoimmune disease	17
P113 Cellular profiling of synovial fluid in inflammatory arthritis highlights disease-specific cell states with biological and diagnostic relevance	17
P066 Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients	17
P247 Novel therapeutic peptides targeting CD206 modulate ATP-induced release of inflammatory and B cell activating factors in lupus macrophages	17
P055 Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum	17
64 Conical teeth? Think outside the box!	17
Multicentric Castleman disease presenting with frequent urination	17
61 The nailfold videocapillaroscopy in pediatric Behçet’s disease: a multi-center study	17
P139 Impact of hand function impairment on daily life of patients with systemic sclerosis - a qualitative study	17
P081 Is it necessary to test vitamin D prior to zoledronate or denosumab treatment?	17
OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications	17
P117 Remote monitoring of rheumatoid arthritis using RAPID3 to support patient-initiated follow up	17
P303 Development of a Behçet’s disease specific patient concerns inventory	17
OA28 VEXAS, a service evaluation in Rheumatology at Sheffield: “Seek, and ye shall find”	17
P229 Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis	17
P012 Pneumocystis jirovecii pneumonia in rheumatology patients - a single centre ten-year audit	17
P038 The importance of looking carefully for the cause(s)	17
56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy	17
P127 A retrospective cohort study assessing outcomes and safety in patients receiving low dose vs high dose cyclophosphamide in myositis interstitial lung disease	17
Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study	16
Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease	16
P278 Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis patients through 52 weeks: data from three phase III,	16
P177 Investigating the neural differences in individuals with chronic widespread pain or fibromyalgia and the effect of sleep: a cross-sectional study using data from UK Biobank	16
E29 Juvenile Idiopathic Arthritis (JIA) in Algeria, from diagnosis to management	16
P156 Type I interferon is raised across connective tissue diseases and is associated with haematological abnormalities and specific autoantibody profiles	16
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease	16
The SUMO components in rheumatoid arthritis	16
P274 The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDs, at 52 weeks in pa	16
77 Case series of juvenile scleroderma from Nigeria	16
P123 Biologic dose tapering: a patient perspective	16
P293 Tocilizumab for refractory or relapsing giant cell arteritis: audit data from the Bristol and Bath regional multidisciplinary meetings 2018-2021	16
Where are we now in biologic drugs for myositis?	16
Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease?	16
P133 Anti-synthetase syndrome: an experience from a tertiary referral center	16
P257 Are there regional variations in access to biological disease modifying anti-rheumatic drugs for the treatment of psoriatic arthritis in England?	16
P106 Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial	16
E048 A review of published data on reported staffing ratios for rheumatology specialist physiotherapists in rheumatology departments	16